An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Infinity Pharmaceuticals (NASDAQ: INFI) will host a conference call on November 2, 2021, at 4:30 PM ET to discuss its financial results for Q3 2021. The call will feature updates on eganelisib, a novel immuno-oncology treatment aimed at managing tumor immune suppression. This includes progress on various clinical studies: MARIO-275, MARIO-3, and MARIO-1, which explore eganelisib's efficacy in combination with other therapies for advanced cancers. Interested parties can access the call via webcasting on Infinity's website.
Positive
Infinity is advancing multiple clinical studies for eganelisib, which could enhance its market position in immuno-oncology.
The upcoming conference call provides an opportunity for investors to gain insights into Q3 financial results and future developments.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, which addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Tuesday, November 2nd 2021, at 4:30pm ET to report its financial results for the third quarter of 2021.
Conference call & Webcast Details
Date: Tuesday, November 2
Time: 4:30 pm Eastern Time Webcast: https://edge.media-server.com/mmc/p/rzfwipgi
Toll Free: (877) 316-5293
International: (613) 291-4526
ID Number: 2938945
A live webcast of the conference call can be accessed in the Investors/ Media section of Infinity’s website at www.infi.com and will be available on Infinity's website for 30 days following the event.
About Infinity and Eganelisib
Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc. Abraxane® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin® is a registered trademark of Genentech, Inc. Doxil® is a registered trademark of Baxter Healthcare Corporation.
When will Infinity Pharmaceuticals report its Q3 2021 financial results?
Infinity Pharmaceuticals will report its Q3 2021 financial results on November 2, 2021, at 4:30 PM ET.
What is eganelisib and its significance in Infinity Pharmaceuticals' pipeline?
Eganelisib is a potentially first-in-class oral immuno-oncology therapeutic aimed at reprogramming macrophages to counter cancer-related immune suppression.
How can I access the conference call for Infinity Pharmaceuticals?
The conference call can be accessed through a live webcast available on Infinity's website.
What clinical studies is Infinity Pharmaceuticals conducting with eganelisib?
Infinity is conducting several studies including MARIO-275, MARIO-3, and MARIO-1 to evaluate eganelisib in combination with approved therapies for advanced cancers.
